Millennium Management’s Elevation Oncology ELEV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-1,424,446
| Closed | -$523K | – | 6121 |
|
|
2025
Q2 | $523K | Buy |
+1,424,446
| New | +$475K | ﹤0.01% | 4881 |
|
|
2025
Q1 | – | Sell |
-815,916
| Closed | -$459K | – | 5985 |
|
|
2024
Q4 | $459K | Buy |
815,916
+30,466
| +4% | +$18K | ﹤0.01% | 4820 |
|
|
2024
Q3 | $471K | Buy |
+785,450
| New | +$1.16M | ﹤0.01% | 4878 |
|
|
2024
Q2 | – | Sell |
-668,573
| Closed | -$3.43M | – | 6030 |
|
|
2024
Q1 | $3.43M | Sell |
668,573
-2,321,706
| -78% | -$7.52M | ﹤0.01% | 3258 |
|
|
2023
Q4 | $1.61M | Sell |
2,990,279
-41,935
| -1% | -$22.2K | ﹤0.01% | 3790 |
|
|
2023
Q3 | $2.01M | Buy |
3,032,214
+715,788
| +31% | +$724K | ﹤0.01% | 3542 |
|
|
2023
Q2 | $3.52M | Buy |
+2,316,426
| New | +$6.11M | ﹤0.01% | 2979 |
|
|
2022
Q3 | – | Sell |
-21,573
| Closed | -$30K | – | 7162 |
|
|
2022
Q2 | $30K | Buy |
+21,573
| New | +$54.2K | ﹤0.01% | 6364 |
|
|
2022
Q1 | – | Sell |
-10,463
| Closed | -$63K | – | 7036 |
|
|
2021
Q4 | $63K | Buy |
+10,463
| New | +$72.2K | ﹤0.01% | 6413 |
|
|
2021
Q3 | – | Sell |
-123,062
| Closed | -$1.67M | – | 6888 |
|
|
2021
Q2 | $1.67M | Buy |
+123,062
| New | +$1.52M | ﹤0.01% | 4172 |
|
Other funds holding ELEV
Millennium Management's ELEV Position: Q3 2025 in Review
Millennium Management sold out of Elevation Oncology (ELEV) in Q3 2025, closing a stake of 1,424,446 shares — an estimated $523K sold.
Millennium Management first reported a position in ELEV in Q2 2021 and held it in 10 quarters. The position peaked at $3.52M in Q2 2023. 1 fund tracked by Wall St. Rank holds ELEV as of Q3 2025.
- Millennium Management reported no remaining Elevation Oncology position as of Q3 2025 after selling out during the quarter.
- Millennium Management sold 1,424,446 Elevation Oncology shares in Q3 2025, an estimated $523K.
- Millennium Management first reported a position in Elevation Oncology in Q2 2021 and held it in 10 quarters.
- Millennium Management's Elevation Oncology position peaked at $3.52M in Q2 2023.
- 1 fund tracked by Wall St. Rank held Elevation Oncology as of Q3 2025.
Based on Millennium Management's 13F filing for Q3 2025, filed 14 Nov 2025.